Literature DB >> 7666781

Pioglitazone attenuates diet-induced hypertension in rats.

L N Kaufman1, M M Peterson, L M DeGrange.   

Abstract

Consumption of diets rich in fats or sugars is correlated with the onset of insulin resistance and hypertension in rats. In the present study, rats were fed diets that induce hypertension; 50% of the rats were also treated with pioglitazone, a thiazolidinedione derivative that sensitizes target tissues to insulin and decreases plasma insulin concentration in insulin-resistant animals. Pioglitazone treatment prevented the development of hypertension and reduced plasma insulin concentration by 70% and 37% in rats fed a high-fat or glucose diet, respectively (P < .05 compared with rats fed the same diet without pioglitazone). In rats fed a control diet, neither insulin nor blood pressure (BP) was affected by pioglitazone treatment. The effect of pioglitazone on insulin and BP could not be attributed to a reduction in body weight, since pioglitazone increased the weight gain of rats fed the high-fat or glucose diet. These findings suggest that in rats fed a diet high in fat or glucose, treatment with pioglitazone maintains plasma insulin concentration and BP at control levels, regardless of body weight.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666781     DOI: 10.1016/0026-0495(95)90000-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

Review 1.  Insulin resistance in non-insulin-dependent diabetes mellitus. A review.

Authors:  A A Alzaid
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

Review 2.  PPAR-γ -- a possible drug target for complicated pregnancies.

Authors:  Fergus P McCarthy; Aoife C Delany; Louise C Kenny; Sarah K Walsh
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

3.  Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone.

Authors:  Y Furuse; K Ogino; M Shimoyama; N Sasaki; I Hisatome
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 4.  Pioglitazone.

Authors:  P S Gillies; C J Dunn
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 5.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.

Authors:  S Takatori; Y Zamami; N Yabumae; N Hanafusa; M Mio; T Egawa; H Kawasaki
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

7.  A meta-analysis of the effect of thiazolidinediones on blood pressure.

Authors:  Rehan Qayyum; Jurga Adomaityte
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

8.  Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats.

Authors:  Dengfeng Gao; Ning Ning; Guanghua Hao; Xiaolin Niu
Journal:  PPAR Res       Date:  2012-04-01       Impact factor: 4.964

Review 9.  Role of the Peroxisome Proliferator Activated Receptors in Hypertension.

Authors:  Shi Fang; M Christine Livergood; Pablo Nakagawa; Jing Wu; Curt D Sigmund
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 23.213

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.